StockWireNews
Breaking News Has Nasdaq Profile (MYNZ) Making Early Green Moves (Low Float - Pull Up Now)
September 28th
Greetings Readers,
MYNZ is off to a strong green start this morning and it could just be the start.
Earlier this AM, MYNZ dropped some big news. Check it out:
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Fi-nan-cial Strategy
Company to Hold Extraordinary General Meeting Week of December 12, 2022
BERKELEY, Calif. and MAINZ, Germany, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its Nominating Committee and Board of Directors nominated Dr. Heiner Dreismann as Chairman of the Board and Gregory Tibbitts to its Board of Directors. The Company’s Board of Directors intends to call an extraordinary general meeting the week of December 12, 2022, to vote on the nominations.
“As we continue to build strength throughout our organization, we are honored to nominate Heiner and Gregory to our Board of Directors, two notable leaders in key areas of the diagnostics field,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The rich experience they would bring to our board, in both strategic development and fi-nan-cial stewardship, will be of significant value as we prepare for our imminent and pivotal US clinical trial for ColoAlert and continue to advance the development and commercialization of our portfolio of next-generation early-cancer detection products.”
...
Read the full article here.
Remember, as I mentioned in previous messages, this is a bounce/reversal idea.
With multiple technicals including 9-Day and 14-Day Relative Strength Indices below 30%, MYNZ could be trading from oversold leaning areas signaling a healthy reversal may be nearing.
Plus, don't forget, this was a multi-time short term runner after my alerts in the past.
Could we see MYNZ pop for the 3rd time?
If you haven't yet, read my initial report below and get this profile on your radar quickly.
-----
The opening bell is bearing down on us and I've got a past champ Nasdaq idea back on notice.
Not only is this a past champ, it's a 2X past champ.
When it was originally brought to your attention, it made an insane move of approximately over 200% in the short term (multi-dollar mover).
Noticing it could be breakout bound once again, it was delivered to my followers' inboxes only to watch it pop another 30+% in a very little period of time.
Pair that knowledge with the fact that I delivered two profiles last week that surged 22% and 25% short term, and you'd be foolish not to get this idea on radar immediately.
Plus, with a low float providing the potential for daily volatility, multiple oversold leaning technicals signaling a possible healthy reversal could be nearing, and TipRanks reporting it to have a $25 price target, this Nasdaq profile needs full focus Wednesday.
Right now this 2X champ requires complete attention:
*Mainz Biomed B.V. (MYNZ)*
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.
And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know:
No. 1 - Low Float Volatility Could Be On Display Daily
No. 2 - An H.C. Wainwright $25 Price Target
No. 3 - This 2X Past Champ Oozes With Bounce/Reversal Potential
No. 4 - Key Company Highlights Provide A Bullish Future Outlook
No. 5 - Commercial Availability of ColoAlert Grows
But more on those in a second...
About MYNZ: Early Identification Of Cancer Saves Lives
Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.
Developing market-ready molecular in-vitro diagnostics tests since 2010.
Their goal is to place effective solutions where they need to be… In your hands.
A Blockbuster Early Detection Test for Colorectal Cancer
Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.
Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022.
U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year.
Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.
Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.
Attractive Valuation: They believe their current valuation holds tremendous upside.
